DySIS Medical Appoints Chairman
News Jan 07, 2014
Mr. Cascella was previously Chief Executive Officer and President of Hologic Inc., a leading manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products for Women’s Healthcare, between 2003 and 2013. He has over 30 years of senior management, operational and finance experience. Prior to Hologic, Mr. Cascella served as Managing Partner of CFG Capital LLC, an investment banking firm specialising in healthcare and was the Chief Operating Officer and Vice President of Finance at NeoVision Corporation, a developer of 3D ultrasound technology used for real-time guidance of interventional breast procedures.
Alastair Atkinson, CEO of DySIS Medical, said: “We welcome Robert as Chairman. His industry knowledge, market and technology expertise and extensive connections in the Women’s Healthcare industry add substantial value to our team. I look forward to working with him to move DySIS into the next stage of growth and expansion.
“I look forward to working with Alastair and the team on the commercialisation strategy of a technology capable of significantly improving upon the diagnostic protocols for cervical disease,” Mr. Cascella added. “DySIS has the unique opportunity to increase the effectiveness of the current standard of care in developed markets, while potentially addressing an unmet healthcare need in emerging markets, where the diagnosis and treatment of cervical disease remains woefully inadequate.”
DySIS Medical, a medical devices company active within Women’s Health, has developed an advanced cervical scan which, in addition to performing traditional colposcopy examinations, uses dynamic spectral imaging to scan, quantify and map the cervix.
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE